Small-cell lung cancer (SCLC), frequently characterized by early metastasis and rapid development of therapy resistance, remains the most aggressive form of lung cancer. Recent transcriptional profiling has redefined SCLC as a heterogeneous spectrum of biologically distinct subtypes with potential differential therapeutic vulnerabilities, fostering optimism that molecular stratification may improve clinical outcomes. Within this framework, growing interest has focused on the rare subset of SCLC that retains functional retinoblastoma (Rb) protein.
Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 03 Apr 2026.
The item focuses on Retinoblastoma Proficient Small Cell Carcinoma: A Novel Entity with Therapeutic Vulnerability?.
Review the original article for the full source wording and details.